
    the termination was due to business reasons. no safety or efficacy concerns contributed to the
    termination of the study
  
['asthma']
['placebo', 'pf-03715455']

        Inclusion Criteria:

          -  Subjects with a physician documented history or diagnosis of persistent asthma
             (according to GINA, 2014 definition of asthma),

          -  Pre bronchodilator FEV1 of greater than or equal to 50 and less that 80% of predicted.

          -  Subjects defined as GINA Step 4 on a stable dose of either fluticasone/salmeterol
             combination therapy, or budesonide/formoterol combination therapy or
             mometasone/formoterol combination therapy.

          -  Subjects who are defined as uncontrolled as evidenced by; Juniper Asthma Control
             Questionnaire (5 item version, ACQ) score greater than or equal to 1.5 and less than
             or equal to 3.0)

        Exclusion Criteria:

          -  Subjects diagnosed with chronic pulmonary disease (COPD) and/or other chronic
             pulmonary diseases (eg, Occupational asthma, pulmonary fibrosis, bronchiectasis,
             Allergic bronchopulmonary aspergillosis (ABPA), pneumoconiosis, sarcoidosis,
             tuberculosis).

          -  Subjects who are current smokers.
      